GYRE
NASDAQ · Biotechnology
Gyre Therapeutics Inc
$7.30
+0.36 (+5.19%)
Open$7.11
Previous Close$6.94
Day High$7.32
Day Low$7.11
52W High$13.75
52W Low$6.11
Volume—
Avg Volume51.7K
Market Cap765.30M
P/E Ratio115.07
EPS$0.06
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+309.9% upside
Current
$7.30
$7.30
Target
$29.92
$29.92
$20.05
$29.92 avg
$33.42
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 93.64M | 231.94M | 230.03M |
| Net Income | 10.70M | -34,891,358 | -29,454,556 |
| Profit Margin | 11.4% | -15.0% | -12.8% |
| EBITDA | 20.56M | -32,635,653 | -32,852,234 |
| Free Cash Flow | — | -26,269,864 | -27,800,469 |
| Rev Growth | +143.3% | -3.5% | +14.1% |
| Debt/Equity | — | 0.25 | 0.21 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |